Literature DB >> 2913056

Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. Studies in rats and patients.

P B Watkins1, S A Murray, L G Winkelman, D M Heuman, S A Wrighton, P S Guzelian.   

Abstract

The major P-450IIIA gene family member present in human liver is HLp which, like its rat liver orthologue P-450p, is inducible by glucocorticoids and catalyzes erythromycin N-demethylation. To develop a practical method to estimate the amounts of HLp in patients [14C]N-methyl erythromycin was injected into rats that had been pretreated with dexamethasone or with inducers of other forms of cytochrome P-450. The rate of demethylation of this substrate, measured simply as 14CO2 in the breath, correlated well with the concentrations of immunoreactive P-450p protein (r = 0.70), holocytochrome P-450p (r = 0.70), or with erythromycin N-demethylase activity (r = 0.90) determined in the liver microsomes prepared from each rat. Next, [14C]N-methyl erythromycin was administered to 30 patients and there was a sixfold interindividual variation in breath 14CO2 production seemingly unrelated to medications, smoking status or age. However, the average breath test values were twofold greater in female as compared to male patients (P less than 0.01). Breath 14CO2 production rose in patients retested after treatment with the P-450IIIA inducers dexamethasone (P less than 0.05) or rifampicin (P less than 0.05) and was decreased after treatment with the HLp inhibitor triacetyloleandomycin (P less than 0.05). We conclude that the erythromycin breath test provides a convenient assay of P-450IIIA cytochromes in rats and in some patients.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2913056      PMCID: PMC303730          DOI: 10.1172/JCI113933

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  43 in total

1.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

2.  The 14CO2 breath test: facilities and limitations of a rapid and noninvasive method for in vivo evaluation of modified hepatic cytochrome P-450--a critique.

Authors:  M Brüch; L Kling; W Legrum; E Maser
Journal:  Arch Toxicol       Date:  1987       Impact factor: 5.153

3.  Regulation of cytochrome P-450j, a high-affinity N-nitrosodimethylamine demethylase, in rat hepatic microsomes.

Authors:  P E Thomas; S Bandiera; S L Maines; D E Ryan; W Levin
Journal:  Biochemistry       Date:  1987-04-21       Impact factor: 3.162

4.  Immunochemical evidence for multiple steroid-inducible hepatic cytochromes P-450 in the rat.

Authors:  K A Hostetler; S A Wrighton; P Kremers; P S Guzelian
Journal:  Biochem J       Date:  1987-07-01       Impact factor: 3.857

5.  Cyclosporine metabolism in human liver: identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs.

Authors:  T Kronbach; V Fischer; U A Meyer
Journal:  Clin Pharmacol Ther       Date:  1988-06       Impact factor: 6.875

6.  Purification of a human liver cytochrome P-450 immunochemically related to several cytochromes P-450 purified from untreated rats.

Authors:  S A Wrighton; P E Thomas; P Willis; S L Maines; P B Watkins; W Levin; P S Guzelian
Journal:  J Clin Invest       Date:  1987-10       Impact factor: 14.808

7.  MPTP, the neurotoxin inducing Parkinson's disease, is a potent competitive inhibitor of human and rat cytochrome P450 isozymes (P450bufI, P450db1) catalyzing debrisoquine 4-hydroxylation.

Authors:  R Fonne-Pfister; M J Bargetzi; U A Meyer
Journal:  Biochem Biophys Res Commun       Date:  1987-11-13       Impact factor: 3.575

8.  Human liver microsomal steroid metabolism: identification of the major microsomal steroid hormone 6 beta-hydroxylase cytochrome P-450 enzyme.

Authors:  D J Waxman; C Attisano; F P Guengerich; D P Lapenson
Journal:  Arch Biochem Biophys       Date:  1988-06       Impact factor: 4.013

9.  Characterization of the common genetic defect in humans deficient in debrisoquine metabolism.

Authors:  F J Gonzalez; R C Skoda; S Kimura; M Umeno; U M Zanger; D W Nebert; H V Gelboin; J P Hardwick; U A Meyer
Journal:  Nature       Date:  1988-02-04       Impact factor: 49.962

10.  Studies on the pregnenolone-16 alpha-carbonitrile-inducible form of rat liver microsomal cytochrome P-450 and UDP-glucuronosyltransferase.

Authors:  M P Arlotto; A J Sonderfan; C D Klaassen; A Parkinson
Journal:  Biochem Pharmacol       Date:  1987-11-15       Impact factor: 5.858

View more
  58 in total

1.  Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine.

Authors:  P Damkier; L L Hansen; K Brosen
Journal:  Br J Clin Pharmacol       Date:  1999-12       Impact factor: 4.335

2.  Sex and age differences in the pharmacokinetics of alosetron.

Authors:  K M Koch; J L Palmer; N Noordin; J J Tomlinson; C Baidoo
Journal:  Br J Clin Pharmacol       Date:  2002-03       Impact factor: 4.335

3.  Evolutionarily divergent electron donor proteins interact with P450MT2 through the same helical domain but different contact points.

Authors:  H K Anandatheerthavarada; G Amuthan; G Biswas; M A Robin; R Murali; M R Waterman; N G Avadhani
Journal:  EMBO J       Date:  2001-05-15       Impact factor: 11.598

Review 4.  Cytochrome P450 3A and their regulation.

Authors:  Oliver Burk; Leszek Wojnowski
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-10-21       Impact factor: 3.000

5.  Effects of CYP3A inhibition on the metabolism of cilostazol.

Authors:  A Suri; W P Forbes; S L Bramer
Journal:  Clin Pharmacokinet       Date:  1999       Impact factor: 6.447

Review 6.  The erythromycin breath test for the prediction of drug clearance.

Authors:  L P Rivory; K A Slaviero; J M Hoskins; S J Clarke
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

7.  Human liver mitochondrial cytochrome P450 2D6--individual variations and implications in drug metabolism.

Authors:  Michelle Cook Sangar; Hindupur K Anandatheerthavarada; Weigang Tang; Subbuswamy K Prabu; Martha V Martin; Miroslav Dostalek; F Peter Guengerich; Narayan G Avadhani
Journal:  FEBS J       Date:  2009-05-11       Impact factor: 5.542

8.  Evaluation of 4β-Hydroxycholesterol and 25-Hydroxycholesterol as Endogenous Biomarkers of CYP3A4: Study with CYP3A-Humanized Mice.

Authors:  Shin-Ichiro Nitta; Mari Hashimoto; Yasuhiro Kazuki; Shoko Takehara; Hiraku Suzuki; Mitsuo Oshimura; Hidetaka Akita; Kan Chiba; Kaoru Kobayashi
Journal:  AAPS J       Date:  2018-04-09       Impact factor: 4.009

Review 9.  The use of therapeutic drug monitoring to optimise immunosuppressive therapy.

Authors:  S M Tsunoda; F T Aweeka
Journal:  Clin Pharmacokinet       Date:  1996-02       Impact factor: 6.447

10.  The influence of CYP3A5 genotype on dexamethasone induction of CYP3A activity in African Americans.

Authors:  Patrick J Roberts; Kristan D Rollins; Angela D M Kashuba; Mary F Paine; Andrew C Nelsen; Eric E Williams; Cassandra Moran; Jatinder K Lamba; Erin G Schuetz; Roy L Hawke
Journal:  Drug Metab Dispos       Date:  2008-05-19       Impact factor: 3.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.